We are analyzing https://link.springer.com/article/10.1007/s00262-003-0409-4.

Title:
Naturally occurring B-cell responses to breast cancer | Cancer Immunology, Immunotherapy
Description:
As demonstrated by the effectiveness of trastuzumab, antibodies against breast cancer antigens are a potentially potent mechanism of tumor control. While trastuzumab is administered exogenously, its efficacy suggests that induction of very high titer antibody responses in vivo might also be therapeutic. Both naturally occurring and vaccine-induced antibody responses to some breast cancer antigens are associated with improved survival in some cases. However, the improvement in survival associated with antibody responses to breast cancer is modest, and tumor regression is not known to be associated with the natural antitumor antibody response, indicating a need for improved understanding of the natural antitumor antibody response. Naturally occurring B-cell responses in the form of serum antibody, tumor reactive lymph node B cells, and tumor-infiltrating B cells have been described, and a variety of breast tumor–associated antigens have been identified based on reactivity of patient antibodies. This review discusses current knowledge of humoral immunity to breast cancer with regard to specific antigens and the basis for their immunogenicity, and the contexts (tumor, lymph node, serum) in which responses are observed. With few exceptions, "tumor-associated antigens" identified with naturally occurring antibodies may be overexpressed on tumor but are in fact nonspecific autoantigens. This suggests that while overexpression or aberrant processing can increase immunogenicity in some cases, the immunogenicity of many or even most tumor-associated antigens is a function of expression in tumor or the result of ancillary tumor factors.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

google, scholar, pubmed, cas, cancer, breast, article, human, res, patients, cells, antibodies, tumor, carcinoma, antibody, immunol, immune, clin, monoclonal, cell, mammary, protein, antigens, response, med, lymph, responses, humoral, natl, expression, oncol, antigen, muc, sci, int, proc, acad, mucin, lymphocytes, biol, survival, reactive, treat, medullary, herneu, exp, immunother, node, tumorassociated, eur,

Topics {✒️}

granulocyte/monocyte-colony stimulating factor month download article/chapter e75-specific tumor-lytic ctls tnf-alpha-induced tu-11 gene antigen-induced b-cell death orbital tissue-infiltrating b-cells ferritin h-chain mrna mouse mammary tumor-virus von mensdorff-pouilly enzyme-linked immunosorbent assay v-fos transformation effector high density o-glycosylation vaccine-induced antibody responses low-dose intravenous cyclophosphamide anti-her2 monoclonal antibodies direct intra-tumor injection igg-recognizing shed tumor phage-displayed cdna libraries monoclonal antibody-defined phenotypes anti-erbb-2 monoclonal antibodies anti-tumor antibody produced tumour-draining lymph nodes c-myc oncogene product anti-sialyl-tn antibodies human b-cell line vivo anti-tumour effects fas-induced apoptosis analyzed cd40 ligand-positive cd8+ 2/neu protein-specific antibody critical review--part ii sialyl-tn epitopes correlate phage-displayed cdna library germinal-centre immune responses 2/neu-targeted immune responses tamoxifen-resistant tumorigenic growth nucleic-acid-binding protein early-stage breast cancer her2/neu extracellular domain antigen-driven clonal proliferation anti-malignin antibody test c-terminal region infiltrating dendritic/langerhans cells antigen-driven oligoclonal expansion article coronella-wood chemokine response profiles early-onset breast carcinomas antigen-specific immunotherapy full article pdf humanized monoclonal antibody c-erbb-2 product

Questions {❓}

Dion AS, Girardi AJ, Williams CC, Pomenti AA, Redfield ES (1987) Responses of serum from breast cancer patients to murine mammary tumor virus: fact or artifact?
Selenko N, Majdic O, Jager U, Sillaber C, Stockl J, Knapp W (2002) Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Naturally occurring B-cell responses to breast cancer
         description:As demonstrated by the effectiveness of trastuzumab, antibodies against breast cancer antigens are a potentially potent mechanism of tumor control. While trastuzumab is administered exogenously, its efficacy suggests that induction of very high titer antibody responses in vivo might also be therapeutic. Both naturally occurring and vaccine-induced antibody responses to some breast cancer antigens are associated with improved survival in some cases. However, the improvement in survival associated with antibody responses to breast cancer is modest, and tumor regression is not known to be associated with the natural antitumor antibody response, indicating a need for improved understanding of the natural antitumor antibody response. Naturally occurring B-cell responses in the form of serum antibody, tumor reactive lymph node B cells, and tumor-infiltrating B cells have been described, and a variety of breast tumor–associated antigens have been identified based on reactivity of patient antibodies. This review discusses current knowledge of humoral immunity to breast cancer with regard to specific antigens and the basis for their immunogenicity, and the contexts (tumor, lymph node, serum) in which responses are observed. With few exceptions, "tumor-associated antigens" identified with naturally occurring antibodies may be overexpressed on tumor but are in fact nonspecific autoantigens. This suggests that while overexpression or aberrant processing can increase immunogenicity in some cases, the immunogenicity of many or even most tumor-associated antigens is a function of expression in tumor or the result of ancillary tumor factors.
         datePublished:2003-08-15T00:00:00Z
         dateModified:2003-08-15T00:00:00Z
         pageStart:715
         pageEnd:738
         sameAs:https://doi.org/10.1007/s00262-003-0409-4
         keywords:
            Antibody
            B cell
            Breast cancer
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0409-4/MediaObjects/s00262-003-0409-4fhc1.jpg
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:52
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Julia A. Coronella-Wood
               affiliation:
                     name:University of Arizona
                     address:
                        name:Arizona Cancer Center, University of Arizona, Tucson, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Evan M. Hersh
               affiliation:
                     name:University of Arizona
                     address:
                        name:Arizona Cancer Center, University of Arizona, Tucson, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Naturally occurring B-cell responses to breast cancer
      description:As demonstrated by the effectiveness of trastuzumab, antibodies against breast cancer antigens are a potentially potent mechanism of tumor control. While trastuzumab is administered exogenously, its efficacy suggests that induction of very high titer antibody responses in vivo might also be therapeutic. Both naturally occurring and vaccine-induced antibody responses to some breast cancer antigens are associated with improved survival in some cases. However, the improvement in survival associated with antibody responses to breast cancer is modest, and tumor regression is not known to be associated with the natural antitumor antibody response, indicating a need for improved understanding of the natural antitumor antibody response. Naturally occurring B-cell responses in the form of serum antibody, tumor reactive lymph node B cells, and tumor-infiltrating B cells have been described, and a variety of breast tumor–associated antigens have been identified based on reactivity of patient antibodies. This review discusses current knowledge of humoral immunity to breast cancer with regard to specific antigens and the basis for their immunogenicity, and the contexts (tumor, lymph node, serum) in which responses are observed. With few exceptions, "tumor-associated antigens" identified with naturally occurring antibodies may be overexpressed on tumor but are in fact nonspecific autoantigens. This suggests that while overexpression or aberrant processing can increase immunogenicity in some cases, the immunogenicity of many or even most tumor-associated antigens is a function of expression in tumor or the result of ancillary tumor factors.
      datePublished:2003-08-15T00:00:00Z
      dateModified:2003-08-15T00:00:00Z
      pageStart:715
      pageEnd:738
      sameAs:https://doi.org/10.1007/s00262-003-0409-4
      keywords:
         Antibody
         B cell
         Breast cancer
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0409-4/MediaObjects/s00262-003-0409-4fhc1.jpg
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:52
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Julia A. Coronella-Wood
            affiliation:
                  name:University of Arizona
                  address:
                     name:Arizona Cancer Center, University of Arizona, Tucson, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Evan M. Hersh
            affiliation:
                  name:University of Arizona
                  address:
                     name:Arizona Cancer Center, University of Arizona, Tucson, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:52
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Arizona
      address:
         name:Arizona Cancer Center, University of Arizona, Tucson, USA
         type:PostalAddress
      name:University of Arizona
      address:
         name:Arizona Cancer Center, University of Arizona, Tucson, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Julia A. Coronella-Wood
      affiliation:
            name:University of Arizona
            address:
               name:Arizona Cancer Center, University of Arizona, Tucson, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Evan M. Hersh
      affiliation:
            name:University of Arizona
            address:
               name:Arizona Cancer Center, University of Arizona, Tucson, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Arizona Cancer Center, University of Arizona, Tucson, USA
      name:Arizona Cancer Center, University of Arizona, Tucson, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(565)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.68s.

LINK . SPRINGER . COM {}